**Title page**

# The Role of CRP, Interleukin-6 and Their Derived Immune-Inflammatory Indices in Early Prediction of Severity and Mortality of COVID-19 Patients

**Running title:** CRP and IL-6 in COVID-19

*Sara I. Taha [a*], Aalaa K. Shata [b], Shereen A. Baioumy [c], Shaimaa H. Fouad [d], Shaimaa A. Abdalgeleel [e], Mariam K. Youssef [a]*

[a] Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
[b] Department of Pulmonary Medicine, Faculty of Medicine, Ain Shams university, Cairo, Egypt.
[c] Department of Microbiology and Immunology, Zagazig University, Zagazig, Egypt.
[d] Department of Internal Medicine / Allergy and Clinical Immunology, Ain Shams University, Cairo, Egypt.
e Department of Biostatistics and Epidemiology, National Cancer Institute, Cairo University, Cairo, Egypt.

**Authors:**

**Sara Ibrahim Taha*
Degree: MD Clinical Pathology/Immunology
Lecturer of Clinical Pathology/ Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
E-mail: dr_sara_ib@med.asu.edu.eg ORCID: https://orcid.org/0000-0001-8224-8701

*Aalaa Kamal Shata*
Degree: MD Pulmonary medicine
Lecturer of Pulmonary Medicine, Faculty of Medicine, Ain Shams university, Cairo, Egypt.
E-mail: aalaashata@yahoo.com

*Shereen Atef Baioumy*
Degree: MD Microbiology and Immunology
Lecturer of Microbiology and Immunology, Zagazig University, Zagazig, Egypt.
Email: drshereenatef@yahoo.com ORCID: https://orcid.org/0000-0002-2188-6790?lang=en

*Shaimaa Hani Fouad*
Degree: MD Internal Medicine
Lecturer of Internal Medicine / Allergy and Clinical Immunology, Ain Shams University Cairo, Egypt.
E-mail: shaimaahani@med.asu.edu.eg ORCID: https://orcid.org/0000-0003-4052-9454

*Shaimaa Abdalaleem Abdalgeleel*
Degree: MD Biostatistics and Epidemiology
Lecturer of Biostatistics and Epidemiology, National Cancer Institute, Cairo University, Cairo, Egypt.
E-mail: shaimaa.abdalgeleel@nci.cu.edu.eg ORCID: https://orcid.org/0000-0003-0994-7703

*Mariam Karam Youssef*
Degree: MD Clinical Pathology/Hematology
Lecturer of Clinical Pathology/Hematology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
E-mail: Dr.mariam_karam@hotmail.com ORCID: https://orcid.org/0000-0003-2075-3889/print

[*] **Corresponding Author:**
*Sara Ibrahim Taha*, MD, PhD
Lecturer of Clinical Pathology/ Immunology, Faculty of Medicine, Ain Shams University.
Address: Ain Shams University, Abassia, Cairo, Egypt
Office tel., fax: + (202) 24346308 Mobile: + (20) 1125360009
E-mail: dr_sara_ib@med.asu.edu.eg ORCID: https://orcid.org/0000-0001-8224-8701

**Abstract:**

**Background:** In coronavirus disease 2019 (COVID-19), finding sensitive biomarkers is critical for detecting severe cases early and intervening effectively. **Objectives:** To compare and evaluate the prognostic value of C-reactive protein (CRP), interleukin-6 (IL-6) and their derived immune-inflammatory indices (CRP/albumin (CRP/alb), lymphocyte/CRP (L/CRP), and lymphocyte/IL-6 (L/IL-6)) in COVID-19 patients. **Methods:** On admission, 85 confirmed COVID-19 patients' measured and collected laboratory data were obtained and compared. **Results:** Levels of CRP, IL-6 and CRP/alb were significantly higher (P=0.001) in severe patients and in non-survivors, but L/CRP and L/IL-6 were significantly lower (P=0.001). The best predictive performance for COVID-19 severity was observed at 1.65 for CRP/alb and 260.86 for L/CRP with 84.7% diagnostic accuracy for both. The best diagnostic accuracy for COVID-19 in-hospital mortality was 87.1% by IL-6 at 120 pg/ml and 85.9% by L/IL-6 at 5.40. The performance of the combined prediction was better than the single prediction by one biomarker. IL-6 was an independent risk factor associated with severe disease development (odds ratio (OR): 1.033; 95% confidence interval (CI): 1.002-1.066). **Conclusions:** Pretreatment values of CRP, IL-6 and their derived indices could be included in the diagnostic work-up of COVID-19 to stratify disease severity and predict outcomes.

**Keywords:** *COVID-19; CRP; Interleukin-6; Mortality; Ratio; Severity*.

## 1. INTRODUCTION:

A global pandemic of coronavirus illness 2019 (COVID-19) is presently sweeping the globe, affecting millions of individuals [1]. COVID-19 is more contagious than seasonal influenza, has a longer incubation time, and is linked to a greater hospitalization rate and overall mortality. The virus can be transmitted through the respiratory tract, causing mainly respiratory infection that can rapidly develop into severe pneumonia, respiratory distress, multi-organ failure, and even death [2].

Although the majority of COVID-19 patients recover quickly after appropriate clinical intervention, the moderate type patients, particularly the elderly, obese patients, and those with co-morbidities, can rapidly worsen and become severe, with an increasing rate of ICU admission and mechanical ventilation, indicating a high mortality rate [3].Thus, early identification of potentially severe patients is critical for halting disease progression at an early stage.

Previous studies have found that aberrant immune-inflammatory response and cytokine storm may play an important role in COVID-19 progression [4]. Therefore, this study was performed to assess the predictive efficacy of individual and combination baseline inflammatory indicators; C-reactive protein (CRP) and interleukin-6 (IL-6) together with their derived immune-inflammatory indices (CRP/albumin (CRP/alb), lymphocyte/CRP (L/CRP), and lymphocyte/IL-6 (L/IL-6)) in a cohort of Egyptian COVID-19 patients.

## 2. MATERIALS & METHODS

### *2.1.Ethics:*

The Ain-Shams University Faculty of Medicine Research Ethics Committee's (REC) ethical criteria were followed in this work. After explaining the nature and purpose of the study, each

participant gave verbal informed consent. All patient data was kept private and confidential, and it was solely utilized for research purposes.

### *2.2.Patients:*

Between March and May 2021, 85 adult patients (aged ≥ 18 years) from Quarantine Hospitals of Ain-Shams University (El-Obour Ain Shams University Specialized Hospital and El-demerdash Hospital), Cairo, Egypt, participated in this cohort observational study. A real-time polymerase chain reaction (RT-PCR) test confirmed the diagnosis of COVID-19 in all of the patients. Pregnant women and patients with any hematological diseases, immunodeficiencies, or autoimmune disorders were excluded from the study. The included patients were classified according to their disease severity using the COVID-19 management guideline provided by Ain Shams University Hospitals [5].

### *2.3.Data collection:*

From medical records, epidemiological and clinical data (such as age, sex, underlying diseases or comorbidities, length of hospital stay, need for ICU admission, and patients' outcomes) were collected, as well as laboratory findings from the same day (such as complete blood differential counts and CRP). Patients were followed up on until they were discharged from the hospital or had an in-hospital death.

### 2.4.*Blood sampling and analysis:*

Venous blood samples were taken via venipuncture from all enrolled patients into biochemistry tubes covered with gel for serum separation. The samples were allowed to clot for 30 mins before being centrifuged for 10 mins at 2,500 g. The serum was immediately used to determine albumin level using a Beckman Coulter AU480 autoanalyzer (Beckman Coulter, Inc. 250s. Kraemer Blvd. Brea, CA92821, USA), according to instructions of the Operator’s Manual. The

dynamic range of albumin was 1.5-6.0 g/dL. The remaining sera were kept at -80°C until they were tested for IL-6 using a commercially available Human IL-6 ELISA Kit from RayBiotech Life, Inc., GA, USA [CODE: ELH-IL6-1]. The assay was carried out according to the manufacturer's instructions, with a detection range of 3 pg/ml - 1000 pg/ml.

### *2.5.Calculations:*

Derived immune-inflammatory indices were calculated as follows: L/CRP = lymphocyte (number/µl)/CRP (mg/dl); L/IL-6 = lymphocyte (number/µl)/IL-6 (pg/ml); CRP/alb = CRP (mg/dl)/albumin (g/dl).

### *2.6.Statistical analysis*

Statistical analysis was performed using SPSS 20.0 (IBM Corporation, NY, USA). Descriptive statistics were done using median and percentiles for quantitative non-parametric measures while categorized data were described in numbers and percentages. The Wilcoxon Rank Sum test and Chi-square test were used to compare two groups of quantitative non-parametric and qualitative data, respectively. The predictive performance of each pretreatment biomarker alone and the clinical benefit of biomarkers combinations were assessed by the receiver operating characteristic (ROC) curve. To clarify the predictors, the odds ratio (OR) and its 95% confidence interval (CI) were calculated using logistic regression analysis. The significant probability of error was set at ≤ 0.05.

## 3. **RESULTS:**

### *3.1.Demographic and Clinical Characterization of the Study Cohort*

The 85 patients included in this prospective cohort study comprised 48 (56.5%) males and 37 (43.5%) females with a median (IQR) age of 55 years (42 – 65). Of all, 54.1% (n=46) were non-severe while 45.9% (n=39) were severe. The most prevalent presenting symptoms were dyspnea

(51.8%) and fever (40%). Hypertension (40.0%) and diabetes mellitus (36.5%) were the most common associated co-morbidities. The median (IQR) duration of hospitalization was 10 days (6 – 17), during which 38.8% (n=33) of patients required ICU admission, and 24.7% (n=21) died. Baseline characteristics and laboratory findings of the studied population (n=85) are demonstrated in **table 1.**

### *3.2.Characteristics of COVID-19 patients according to disease severity and in-hospital mortality:*

**Table 2** compares the baseline clinical characteristics and laboratory findings according to severity and in-hospital mortality of COVID-19 patients.

Significant changes between the severity groups were observed when their median (IQR) values were compared. As opposed to the non-severe group, severe patients had significantly higher values of CRP (129 (IQR: 50 – 152) vs.12 (6.5 – 32) mg/L; P ≤ 0.001), IL-6 (120 (80 – 220) vs. 32 (18 – 50) pg/ml; P ≤ 0.001) and CRP/alb (3.87 (1.66 – 4.90) vs. 0.35 (0.15 – 0.64); P ≤ 0.001). And, significantly lower values of L/CRP (105.26 (56.96 – 230.26) vs. 1211.96 (449.82 – 2500); P ≤ 0.001), L/IL-6 (8.33 (4.20 – 14.54) vs. 40.83 (25.20 – 98.71); P ≤ 0.001), lymphocyte count (0.9 (0.5 – 2.2) vs.1.49 (1 – 2.22) $\times 10^3/\mu L$; P=0.028) and albumin ( 3.2 (2.9 – 3.6) vs. 4 (3.1 – 4.8) g/dl; P ≤ 0.001).

Regarding in-hospital mortality of COVID-19, significant differences between survivors and non-survivors were observed. CRP (152 (57.8 – 152) vs.18 (7.7 – 65.75) mg/L;P ≤ 0.001), IL-6 (168 (110 – 275) vs. 45 (20 – 97.5) pg/ml; P ≤ 0.001), and CRP/alb (4.3 (1.82 – 5.52) vs. 0.52 (0.20 – 1.70); P ≤ 0.001) showed significantly higher values in non-survivors compared to survivors. In contrast, L/CRP (105.26 (43.56 – 212.5) vs. 703.27 (186.18 – 2005.35); P ≤ 0.001), L/IL-6 (5.33 (3.34 – 14.55) vs. 29.55 (11.90 – 79); P ≤ 0.001) and albumin (3 (2.75 – 3.6)

vs. 3.75 (3.02 – 4.35) g/dl; P= 0.001) were significantly lower. But, the change in lymphocyte count according to in-hospital mortality was not significant (0.9 (0.55 – 1.96) vs.1.4 (0.77 – 2.2) $\times 10^3/\mu L$; P=0.178).

### *3.3.Predictive performance evaluation:*

**Table 3:** demonstrates diagnostic validity tests and ROC curve analysis that were used to assess each biomarker's overall prognostic performance on its own, identifying those that performed well. Biomarkers with the best diagnostic efficacies (least false and highest true results) were then combined in a multi-ROC curve to maximize the AUC and improve prognostic accuracy.

Regarding COVID-19 severity, whilst CRP alone at a cutoff of 48 mg/L offered 0.861 AUC, and 82.4% diagnostic accuracy, its derived indices, CRP/alb and L/CRP, exhibited the best predictive performance compared to other biomarkers. At the cutoff point of 1.65 for CRP/alb and 260.86 for L/CRP, the AUC was 0.878 and 0.873, respectively, and the diagnostic accuracy was 84.7% for both. And when CRP/alb at a cutoff point of 1.65 was combined with L/CRP at a cutoff point of 2300 in a multi-ROC analysis, COVID-19 severity prediction accuracy increased to 95.3% with an AUC of 0.922. **Figure 1**

With reference to COVID-19 in-hospital mortality, the baseline IL-6 level was the most highly predictive biomarker with 0.88 AUC at a cut-off point of 120 pg/ml and a diagnostic accuracy of 87.1%. Comparable to IL-6 was L/IL-6 with 0.86 AUC at a cut-off point of 5.40 and a diagnostic accuracy of 85.9%. Adding IL-6 at a cutoff point of 120 pg/ml to L/IL-6 at a cutoff point of 8, has improved the overall in-hospital mortality prediction ability and increased the AUC to 0.946 and the diagnostic accuracy to 96.5%. **Figure 2**

### *3.4.Risk factors assessment:*

The association between IL-6, CRP, and their derived indices with COVID-19 severity and in-hospital mortality was further evaluated by logistic regression analysis. As to COVID-19 in-hospital mortality, the multivariate analysis showed that the odds ratios (ORs) of all studied biomarkers were not significantly different between survivors and non-survivors ($p > 0.05$). and only IL-6 was an independent risk that was significantly positively associated with severe disease development (OR: 1.033; 95% CI: 1.002 - 1.066; P =0.037). **Table 4** demonstrates univariate and multivariate logistic regression analyses for possible predictors of COVID-19 severity and in-hospital mortality.

## 4. DISCUSSION

During the current pandemic of COVID-19, since immune dysfunction, hyper-inflammation, and hyper-cytokinaemia have been closely related to the rapid progression of the disease [6], continuous finding of sensitive inflammatory biomarkers for timely and effective identification of disease progression is necessary [7].

CRP is a useful inflammatory biomarker that plays an important role in host resistance to invading pathogens. It was found to be highly related to acute lung injury in COVID-19 patients. Also, higher CRP values have been linked to unfavorable aspects of the disease such as cardiac injury, respiratory distress, and even death. Therefore, the detection of CRP levels is of great value in assessing the severity of COVID-19 patients [8].

In our study, CRP increased significantly with COVID-19 severity and in-hospital mortality. Similarly, several studies have reported a significantly higher CRP values in the more severe patients and in those who died from the disease [8-10]. In contrary, Zhang Y. revealed no significant change in CRP levels in patients after being admitted to ICU [11]. Also, Ferrari and

colleagues, based on statistical analysis, stated that CRP might not be very useful in discriminating between patients with or without COVID-19 [12].

IL-6 is a multifunctional cytokine that regulates immunological and inflammatory responses. It has been found to play a key role in the development and progression of coronavirus pneumonia. In COVID-19 patients with hyper-inflammatory syndrome, circulating IL-6 concentrations have been linked to disease severity, the incidence of acute lung damage, and the need for mechanical ventilation, suggesting that measuring IL-6 levels can help guide therapy decisions. [13].

In our study, IL-6 levels were significantly higher in severe patients and in non-survivors. In accordance to our results, Sun and co-workers reported significantly higher IL-6 values in the more severe patients [13]. Also, Coomes et al. have reported in a systemic review that IL-6 was associated with adverse outcomes in COVID-19 patients [14].

Furthermore, several studies have reported the distinct clinical significance of IL-6 at varying cut-off values. Yong et al. studied a cohort of 43 cases and reported that combining IL-6 at a cut off value of 24.3 pg/ml with the D-Dimer helped in early detection of severe cases [15]. In another cohort by Giofoni et al., serum IL-6 at a cut-off value of 25 pg/ml represented an independent risk of progression to severe disease and/or in-hospital mortality [16]. In a cohort study of 40 patients in Munich, COVID-19 patients' need for mechanical ventilation increased 22 times with the elevated IL-6 levels (> 80 pg/ml) [17].

In a meta-analysis, Coomes and Haghbayan discovered statistical heterogeneity in IL6 levels in subjects with varying degrees of disease severity. They attributed this to inconsistencies of patients' characteristics in each trial, as well as discrepancies in the timing of IL6 testing and immunomodulatory medicines received [14].

Significant hypo-albuminaemia and lymphopenia were discovered in severe patients in the current study; however, only significant hypo-albuminaemia and not lymphopenia was detected in non-survivors. Returning to the fact that albumin levels drop in inflammatory conditions, hypoalbuminemia has been noted in COVID-19 patients with severe hyperinflammation [18].

In a number of studies [3, 19], COVID-19 severity and progression have been linked to lymphopenia, which has been found to be a reliable and accurate prediction. According to a meta-analysis study, the more serious the condition, the less lymphocytes there were [20], which could be attributed to the disease's effect on T cell subsets, resulting in immunological dysfunction. [21&22]. Several have studies emphasized that when the lymphocyte count is less than 1.5 $10^3$/µL, lymphopenia should be addressed [9].

Using an inflammatory biomarker alone to evaluate patients infected with COVID-19 could be influenced by a number of factors. As a result, the generated indices from the most important inflammatory biomarkers may more accurately and thoroughly indicate immunological dysregulation [7, 23].

The L/CRP has been used as a prognostic marker for several types of cancers, including colon and gastric carcinomas. The rationale behind this is that it serves as a good indicator of the complex host-tumor immunological interactions that result in the systemic inflammatory process incriminated in the pathogenesis of these carcinomas [24-26]. COVID-19 also triggers an inflammatory reaction throughout the body therefore, the L/CRP could be used as a useful prognostic biomarker for disease severity and outcome. On exploring the role of L/CRP in prognosis of our studied COVID-19 patients, we found that it declined significantly with the increase in disease severity and mortality. In accordance to our results, Ullah and co-workers

have found that a low L/CRP was a good predictor of in-hospital complications and mortality in COVID-19 patients [24].

High CRP/alb was previously linked to the mortality in critically ill patients of various conditions [27]. In our study, we found a significant elevation of the CRP/alb as the disease progressed. Similarly, El-Shabrawy and colleagues have found that the CRP/alb was a predictive factor of COVID-19 mortality [28].

In our study, the L/IL-6 was much lower in severe COVID-19 patients and non-survivors. In the same context, because high IL-6 levels and low lymphocyte counts have been connected to the severity and in-hospital mortality of COVID-19, in a study by Yang and colleagues, the IL-6/lymphocyte ratio (IL-6/L, reversed) was described as a novel biomarker to conduct risk stratification in COVID-19 patients [7]. Other studies have found that having a high IL-6/L is an independent risk factor for disease progression and a poor prognosis [29, 30]. The decrease in lymphocyte numbers caused by IL-6-mediated inhibition of T cell activation explained the high in COVID-19 [31]. Furthermore, in a study by Jing Liu et al., T cell numbers were inversely associated with the studied cytokine levels, including IL-6 [32]. As a result, the balance of IL-6 and lymphocytes appeared to play a critical role in the regulation of the immune system.

ROC curve analysis was used to assess the overall prognostic performance of each biomarker alone. Then, in a multi-ROC curve analysis, we integrated biomarkers that exhibited the best predictive performance for COVID-19 severity or in-hospital mortality in order to achieve the maximum overall test efficacy and improve the prognostic ability. The combination of CRP/alb and L/CRP improved disease severity prediction accuracy. Similarly, combining IL-6 with the L/IL-6 enhanced in-hospital mortality prediction accuracy. Finally, only IL-6 was found to be positively correlated with disease severity but, none of the investigated biomarkers were shown to be an independent predictor of in-hospital mortality. This could be attributed to the small

sample size, as well as the disproportion between the study groups, and these were the study's major limitations.

More research on a larger scale and for a longer period of time is needed to determine the predictive usefulness of the proposed inflammatory indices in comparison to the other existing biomarkers, in order to slow the disease's progression and to put the epidemic to an end.

## 5. CONCLUSIONS:

The current study discovered that CRP and IL-6, as well as their derived immune-inflammatory indices, namely CRP/alb, L/CRP, and L/IL-6, were good predictors of COVID-19 severity and in-hospital mortality. Using these indicators in combinations rather than a single biomarker alone would improve the overall performance in disease progression prediction.

**Abbreviations:**

*CRP/alb: CRP/albumin; L/CRP: lymphocyte/CRP; L/IL-6: lymphocyte/IL-6.*

**Manuscript word count:** 2575 words

**Abstract word count:** 198 words

**Reference count:** 33

**Figures:** 2

**Tables:** 4

**Data availability statement:** Data will be available upon request.

**Statement of Informed Consent**: Informed consent was obtained from all patients or their first-degree relatives for being included in the study.

**Acknowledgement:** none.

**Conflicts of interest disclosure:** None.

**Funding sources:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Consent for publication:** Not applicable**.**

**Authors contribution:**

**ST and MY** designed the study; **SF and AS** collected clinical samples**; SB, ST and MY** performed research; **SA** analyzed data; **SB, ST, SF and MY** wrote the manuscript**; SA and AS** reviewed and edited the manuscript. All authors contributed to the article and approved the submitted version.

**References:**

**[1]** Chan AS, Rout A. Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19. J Clin Med Res. 2020 Jul;12(7):448-453. doi: 10.14740/jocmr4240. Epub 2020 Jun 25. PMID: 32655740; PMCID: PMC7331861.

**[2]** Feng X, Li S, Sun Q, Zhu J, Chen B, Xiong M, et al. Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2020 Jun 9; 7:301. doi: 10.3389/fmed.2020.00301. PMID: 32582743; PMCID: PMC7295898.

**[3]** Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020 Mar 27;5(1):33. doi: 10.1038/s41392-020-0148-4. PMID: 32296069; PMCID: PMC7100419.

**[4]** Zhu Z, Cai T, Fan L, Lou K, Hua X, Huang Z, et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int J Infect Dis. 2020 Jun; 95:332-339. doi: 10.1016/j.ijid.2020.04.041. PMID: 32334118; PMCID: PMC7195003.

**[5]** Abdelfattah E, Ahmed S, El-Zahapy H, EL Said A, Salem S, Tharwat A, et al. Hospital response to COVID-19 a consensus: Report on Ain Shams University Hospital Strategy. ScienceOpen. [published online ahead of print, June 12, 2020]. doi: https://doi.org/10.14293/S2199-1006.1.SOR-.PPD4QZX.v1

**[6]** Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. PMID: 32192578; PMCID: PMC7270045.

**[7]** Yang B, Chang X, Huang J, Pan W, Si Z, Zhang C, et al. The role of IL-6/Lin the peripheral blood of severe patients with COVID-19. Int Immunopharmacol. 2021 Mar 12; 97:107569. doi: 10.1016/j.intimp.2021.107569. PMID: 33933851; PMCID: PMC7953449.

**[8]** Shang W, Dong J, Ren Y, Tian M, Li W, Hu J, et al. The value of clinical parameters in predicting the severity of COVID-19. J Med Virol. 2020 Oct;92(10):2188-2192. doi: 10.1002/jmv.26031. PMID: 32436996; PMCID: PMC7280691.

**[9]** Kazemi E, Soldoozi Nejat R, Ashkan F, Sheibani H. The laboratory findings and different COVID-19 severities: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob.2021;20(1):17.https://doi.org/10.1186/s12941-021-00420-3.PMID:33726761; PMCID: PMC7962428

**[10]** Danwang C, Endomba FT, Nkeck JR, Wouna DLA, Robert A, Noubiap JJ. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020; 8:37. doi: 10.1186/s40364-020-00217-0. PMID: 32879731; PMCID: PMC7456766

**[11]** Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. Liver. 2020 Sep;40(9):2095-2103. doi: 10.1111/liv.14455. PMID: 32239796.

**[12]** Ferrari D, Motta A, Strollo M, Banfi G, Locatelli M. Routine blood tests as a potential diagnostic tool for COVID-19. Clin Chem Lab Med. 2020;58(7):1095–1099. doi: 10.1515/cclm-2020-0398. PMID: 32301746

**[13]** Sun H, Guo P, Zhang L, Wang F. Serum Interleukin-6 Concentrations and the Severity of COVID-19 Pneumonia: A Retrospective Study at a Single Center in Bengbu City, Anhui

Province, China, in January and February 2020. Med Sci Monit. 2020 Nov 11;26: e926941. doi: 10.12659/MSM.926941. PMID: 33175722; PMCID: PMC7670831.

**[14]** Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. Rev Med Virol. 2020 Nov;30(6): 1-9.doi: 10.1002/rmv.2141.

**[15]** Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020 Jul;92(7):791-796. doi: 10.1002/jmv.25770. PMID: 32181911; PMCID: PMC7228247

**[16]** Grifoni E, et al. Interleukin-6 as prognosticator in patients with COVID-19. J Infect. 2020 Sep;81(3):452-482. doi: 10.1016/j.jinf.2020.06.008. PMID: 32526326; PMCID: PMC7278637.

**[17]** Herold T, Jurinovic V, Arnreich C, Hellmuth JC, von Bergwelt-Baildon M, Klein M, et al. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. https ://doi.org/10.1101/2020.04.01.20047 381. Posted on medRxiv 10 Apr 2020. (preprint)

**[18]** Aziz M, Fatima R, Lee-Smith W, Assaly R. The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis. Crit Care. 2020 May 26;24(1):255. doi: 10.1186/s13054-020-02995-3. PMID: 32456658; PMCID: PMC7249975.

**[19]** Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA. Hematological findings and complications of COVID-19. Am J Hematol. 2020 Jul;95(7):834-847. doi: 10.1002/ajh.25829. Epub 2020 May 23. PMID: 32282949; PMCID: PMC7262337.

**[20]** Pourbagheri-Sigaroodi A, Bashash D, Fateh F, Abolghasemi H. Laboratory findings in COVID-19 diagnosis and prognosis. Clin Chim Acta. 2020; 510:475–82. doi: 10.1016/j.cca.2020.08.019. PMID: 32798514 PMCID: PMC7426219.

**[21]** Tufan A, Güler AA, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020 Apr 21;50(SI-1):620-632. doi: 10.3906/sag-2004-168. PMID: 32299202; PMCID: PMC7195984

**[22]** Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia, J Infect Dis. 2020 May 11;221(11):1762-1769. doi: 10.1093/infdis/jiaa150. PMID: 32227123; PMCID: PMC7184346.

**[23]** Pourbagheri-Sigaroodi A, Bashash D, Fateh F, Abolghasemi H. Laboratory findings in COVID-19 diagnosis and prognosis. Clin Chim Acta. 2020; 510:475–82. doi: 10.1016/j.cca.2020.08.019. PMID: 32798514 PMCID: PMC7426219

**[24]** Sun Y, Dong Y, Wang L, Xie H, Li B, Chang C, et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. J Autoimmun. 2020 Aug; 112: 102473. doi: 10.1016/j.jaut.2020.102473. PMCID: PMC7180376; PMID: 32439209

**[25]** Ullah W, Basyal B, Tariq S, Almas T, Saeed R, Roomi S, et al. Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19. J Clin Med Res. 2020 Jul;12(7):415-422. doi: 10.14740/jocmr4227. Epub 2020 Jun 25. PMID: 32655735; PMCID: PMC7331862.

**[26]** Okugawa Y, Toiyama Y, Yamamoto A, Shigemori T, Ichikawa T, Yin C, Suzuki A, et al. Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-in-

flammation markers of outcome in patients with gastric cancer. Clin Nutr. 2020;39(4):1209-1217. doi: 10.1016/j.clnu.2019.05.009. PMID: 31155370.

**[27]** Okugawa Y, Toiyama Y, Yamamoto A, Shigemori T, Ide S, Kitajima T, et al. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer. Ann Surg. 2020 Aug;272(2):342-351. doi: 10.1097/SLA.0000000000003239. PMID: 32675548.

**[28]** Akirov A, Masri-Iraqi H, Atamna A, Shimon I. Low Albumin Levels Are Associated with Mortality Risk in Hospitalized Patients. Am J Med. 2017 Dec;130(12): 1465.e11-1465.e19. doi: 10.1016/j.amjmed.2017.07.020. Epub 2017 Aug 9. Erratum in: Am J Med. 2020 May;133(5):646. PMID: 28803138.

**[29]** El-Shabrawy M, Alsadik ME, El-Shafei M, Abdelmoaty AA, Alazzouni AS, Esawy MM, Shabana MA. Interleukin-6 and C-reactive protein/albumin ratio as predictors of COVID-19 severity and mortality. Egypt J Bronchol. 2021;15(1):5. doi: 10.1186/s43168-021-00054-1. PMCID: PMC7807221.

**[30]** Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID- 19 patients. Clin Infect Dis. 2020 Nov 5;71(8):1937-1942. doi: 10.1093/cid/ciaa449. PMID: 32301997; PMCID: PMC7184354

**[31]** Chiappelli F, Khakshooy A, Greenberg G. COVID-19 Immunopathology and Immunotherapy, Bioinformation. 16 (3) (2020) 219 – 222. doi: 10.6026/97320630016219. PMID: 32308263; PMCID: PMC7147500

**[32]** Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al., Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708-1720. DOI: 10.1056/NEJMoa2002032

**[33]** Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al., Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients EBioMedicine.2020 May;55:102763. doi: 10.1016/j.ebiom.2020.102763. PMID: 32361250; PMCID: PMC7165294




**Figure 1:** ROC curve analysis showing the diagnostic performance of CRP/alb (AUC:0.878; 95%CI: 0.805-0.952); L/CRP (AUC: 0.873; 95%CI: 0.798-0.948) and their combination (AUC: 0.922) for discriminating severe COVID-19 patients from those non-severe.




**Figure 2:** ROC curve analysis showing the diagnostic performance of L/IL-6 (AUC: 0.866; 95CI: 0.762-0.970); IL-6(AUC: 0.888; 95CI: 0.819-0.957), and their combination (AUC: 0.946) for discriminating survivors from non-survivors in COVID-19.

**Table 1:** Baseline characteristics and laboratory findings of the studied population (n=85)**.**

| Variable | | All Cases (n=85) |
|---|---|---|
| **Age (years)** | Median (IQR) | 55 (42 – 65) |
| | Range | 21 – 85 |
| **Sex n, (%)** | Male | 48 (56.5%) |
| | Female | 37 (43.5%) |
| **Comorbidities n, (%)** | DM | 31 (36.5%) |
| | HTN | 34 (40.0%) |
| | COPD | 7 (8.2%) |
| | IHD | 5 (5.9%) |
| | CLD | 3 (3.5%) |
| | CKD | 15 (17.6%) |
| **Symptoms n, (%)** | Cough | 1 (1.2%) |
| | Cough and dyspnea | 2 (2.4%) |
| | diarrhea | 1 (1.2%) |
| | Dyspnea | 44 (51.8%) |
| | fever | 34 (40.0%) |
| | Fever and Cough | 3 (3.5%) |
| **ICU admission n, (%)** | Positive | 33 (38.8%) |
| | Negative | 52 (61.2%) |
| **Severity n, (%)** | Non-severe | 46 (54.1%) |
| | severe | 39 (45.9%) |
| **Laboratory findings Median (IQR)** | Hemoglobin gm/dl | 12.6 (10.2 – 14.2) |
| | Platelets $\times 10^3$/cmm | 227 (171.5 – 273.5) |
| | Total leukocytic count $\times 10^3$/cmm | 6.9 (4.35 – 10.55) |
| | Lymphocytes $\times 10^3$/cmm | 1.34 (0.7 – 2.2) |
| | Neutrophils $\times 10^3$/cmm | 4.28 (2.39 – 7.86) |
| | Albumin (g/dl) | 3.5 (3 – 4.2) |
| | CRP (mg/L) | 32 (9.5 – 132.5) |
| | IL– 6 (pg/ml) | 55 (25 – 120) |
| | L/CRP | 348.83 (99.78 – 1545.32) |
| | CRP/alb | 0.94 (0.28 – 3.87) |
| | L/IL-6 | 18.97 (8.25 – 51.71) |
| **Hospital stay (days)** | Median (IQR) | 10 (6 – 17) |
| | Range | (2 – 30) |
| **Fate** | Discharged | 64 (75.3%) |
| | Died | 21 (24.7%) |

*CKD: Chronic kidney disease; CLD: Chronic liver disease; COPD: Chronic obstructive pulmonary disease; DM: Diabetes mellitus; HTN: Hypertension; ICU: Intensive care unit; IHD: Ischemic heart disease; IQR: interquartile range.*

**Table 2:** Comparisons of baseline characteristics and laboratory findings according to COVID-19 severity and in-hospital mortality.

| Variable | | Non– severe (n=46) | Severe (n=39) | p– value | Survivors (n=64) | Non–survivors (n=21) | p– value |
|---|---|---|---|---|---|---|---|
| **Age (years)** | Median (IQR) | 55.5 (41.5 – 63) | 55 (43 – 67) | 0.250 | 55.5 (42 – 64.75) | 55 (47 – 69.5) | 0.454 |
| **Sex n, (%)** | Male | 23 (50.0%) | 25 (64.1%) | 0.191 | 34 (53.1%) | 14 (66.7%) | 0.277 |
| | Female | 23 (50.0%) | 14 (35.9%) | | 30 (46.9%) | 7 (33.3%) | |
| **Comorbidities n, (%)** | DM | 13 (28.3%) | 18 (46.2%) | 0.088 | 19 (29.7%) | 12 (57.1%) | 0.023 |
| | HTN | 15 (32.6%) | 19 (48.7%) | 0.131 | 22 (34.4%) | 12 (57.1%) | 0.065 |
| | COPD | 2 (4.3%) | 5 (12.8%) | 0.157 | 3 (4.7%) | 4 (19.0%) | 0.038 |
| | IHD | 0 (0.0%) | 5 (12.8%) | 0.012 | 3 (4.7%) | 2 (9.5%) | 0.414 |
| | CLD | 2 (4.3%) | 1 (2.6%) | 0.657 | 3 (4.7%) | 0 (0.0%) | 0.312 |
| | CKD | 4 (8.7%) | 11 (28.2%) | 0.019 | 10 (15.6%) | 5 (23.8%) | 0.393 |
| **Laboratory parameters Median (IQR)** | Lymp $\times 10^3$/cmm | 1.49 (1 – 2.22) | 0.9 (0.5 – 2.2) | 0.028 | 1.4 (0.77 – 2.2) | 0.9 (0.55 – 1.96) | 0.178 |
| | CRP (mg/L) | 12 (6.5 – 32) | 129) (50 – 152 | ≤ 0.001 | 18 (7.7 – 65.75) | 152 (57.8 – 152) | ≤ 0.001 |
| | Albumin (g/dl) | 4 (3.1 – 4.8) | 3.2 (2.9 – 3.6) | ≤ 0.001 | 3.75 (3.02 – 4.35) | 3 (2.75 – 3.6) | 0.001 |
| | IL– 6 (pg/ml) | 32 (18 – 50) | 120 (80 – 220) | ≤ 0.001 | 45 (20 – 97.5) | 168 (110 – 275) | ≤ 0.001 |
| | L/IL-6 | 40.83 (25.20 – 98.71) | 8.33 (4.20 – 14.54) | ≤ 0.001 | 29.55 (11.90 – 79) | 5.33 (3.34 – 14.55) | ≤ 0.001 |
| | CRP/alb | 0.35 (0.15 – 0.64) | 3.87 (1.66 – 4.90) | ≤ 0.001 | 0.52 (0.20 – 1.70) | 4.3 (1.82 – 5.52) | ≤ 0.001 |
| | L/CRP | 1211.96 (449.82 – 2500) | 105.26 (56.96 – 230.26) | ≤ 0.001 | 703.27 (186.18 – 2005.35) | 105.26 (43.56 – 212.5) | ≤ 0.001 |
| **ICU admission n, (%)** | Positive | 9 (19.6%) | 24 (61.5%) | ≤ 0.001 | 17 (26.6%) | 16 (76.2%) | ≤ 0.001 |
| | Negative | 37 (80.4%) | 15 (38.5%) | | 47 (73.4%) | 5 (23.8%) | |
| **Hospital stay (days)** | Median (IQR) | 10.5 (6.75 – 17.5) | 9 (5 – 14) | 0.112 | 9.5 (6 – 17) | 10 (7 – 16) | 0.759 |
| **Fate** | Discharged | 43 (67.2%) | 21 (32.8%) | ≤ 0.001 | | | |
| | Died | 3 (14.3%) | 18 (85.7%) | | | | |

*CKD: Chronic kidney disease; CLD: Chronic liver disease; COPD: Chronic obstructive pulmonary disease; DM: Diabetes mellitus; HTN: Hypertension; ICU: Intensive care unit; IHD: Ischemic heart disease; IQR: Interquartile range; Lymp: Lymphocytes. Statistical significance set at 0.05.*

**Table 3:** Diagnostic validity and receiver operating curve (ROC) analysis for the ability of CRP, IL-6 and their derived indices to distinguish COVID-19 infected patients according to severity and mortality of the disease.

| Indicators | Cut off | AUC | Specificity % | Sensitivity % | NPV % | PPV % | Accuracy % |
|---|---|---|---|---|---|---|---|
| **Severity** | | | | | | | |
| CRP | 48 | 0.861 | 84.8 | 79.5 | 83.0 | 81.6 | 82.4 |
| IL– 6 | 50 | 0.873 | 78.3 | 87.2 | 87.8 | 77.3 | 82.4 |
| L/IL-6 | 11.66 | 0.883 | 95.7 | 71.8 | 80.0 | 93.3 | 84.7 |
| CRP/alb | 1.65 | 0.878 | 91.3 | 76.9 | 82.4 | 88.2 | 84.7 |
| L/CRP | 260.86 | 0.873 | 89.1 | 79.5 | 83.7 | 86.1 | 84.7 |
| CRP/alb at 1.65 + L/CRP at:2300 | -- | 0.922 | 91.3 | 100.0 | 100.0 | 90.7 | 95.3 |
| **In- hospital mortality** | | | | | | | |
| CRP | 151 | 0.801 | 92.2 | 57.1 | 86.8 | 70.6 | 83.5 |
| IL– 6 | 120 | 0.888 | 92.2 | 71.4 | 90.8 | 75.0 | 87.1 |
| L/IL-6 | 5.40 | 0.866 | 95.3 | 57.1 | 87.1 | 80.0 | 85.9 |
| CRP/alb | 4.21 | 0.812 | 90.6 | 57.1 | 86.6 | 66.7 | 82.4 |
| L/CRP | 129.03 | 0.787 | 79.7 | 61.9 | 86.4 | 50.0 | 75.3 |
| IL-6 at 120 pg/ml + L/IL-6 at:8 | -- | 0.946 | 100.0 | 85.7 | 95.5 | 100.0 | 96.5 |

*AUC: area under curve; CRP/alb = CRP (mg/dl)/albumin (g/dl); CRP: C-reactive protein in mg/L; IL-6: interleukin-6 in pg/mL; L/CRP = lymphocyte (number/μl)/CRP (mg/dl); L/IL-6 = lymphocyte (number/μl)/IL-6 (pg/ml); NPV: negative predictive value; PPV: positive predictive value.*

**Table 4:** Logistic regression analysis for predictors of COVID-19 severity and in-hospital mortality.

| Indicator | Uni-variate | | | | Multi-variate | | | |
|---|---|---|---|---|---|---|---|---|
| | P-value | Odds ratio | 95% C.I. for OR | | P-value | Odds ratio | 95% C.I. for OR | |
| | | | Lower | Upper | | | Lower | Upper |
| **Mortality** | | | | | | | | |
| L/IL-6 | 0.001 | 0.872 | 0.803 | 0.947 | 0.374 | 0.92 | 0.766 | 1.105 |
| CRP/alb | ≤ 0.001 | 1.921 | 1.431 | 2.579 | 0.439 | 2.602 | 0.231 | 29.268 |
| L/CRP | 0.065 | 0.999 | 0.999 | 1 | 0.164 | 1 | 1 | 1.001 |
| CRP (mg/L) | ≤ 0.001 | 1.021 | 1.011 | 1.031 | 0.758 | 0.988 | 0.917 | 1.065 |
| IL– 6 (pg/ml) | ≤ 0.001 | 1.019 | 1.01 | 1.028 | 0.152 | 1.013 | 0.995 | 1.032 |
| **Severity** | | | | | | | | |
| L/IL-6 | 0.001 | 0.945 | 0.914 | 0.976 | 0.652 | 1.006 | 0.981 | 1.032 |
| CRP/alb | ≤ 0.001 | 2.787 | 1.821 | 4.264 | 0.371 | 7.401 | 0.092 | 593.008 |
| L/CRP | ≤ 0.001 | 0.997 | 0.996 | 0.999 | 0.285 | 0.999 | 0.996 | 1.001 |
| CRP (mg/L) | ≤ 0.001 | 1.03 | 1.018 | 1.043 | 0.495 | 0.956 | 0.84 | 1.088 |
| IL– 6 (pg/ml) | ≤ 0.001 | 1.032 | 1.018 | 1.047 | 0.037 | 1.033 | 1.002 | 1.066 |

*CI: Confidence interval*